On September 7, 2022 Novavax, Inc. ( Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, reported that it will participate in two upcoming investor conferences (Press release, Novavax, SEP 7, 2022, View Source [SID1234619208]). Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright 24th Annual Global Investment Conference:
Recordings
All replays of the recorded fireside sessions will be available through the Events & presentations page of the Company’s website at ir.novavax.com for 90 days from the date of the conference.